Zacks Research Analysts Raise Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research upped their Q4 2025 EPS estimates for shares of Corcept Therapeutics in a note issued to investors on Tuesday, January 21st. Zacks Research analyst K. Das now forecasts that the biotechnology company will earn $0.54 per share for the quarter, up from their previous estimate of $0.53. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2026 earnings at $0.73 EPS, Q4 2026 earnings at $0.73 EPS and FY2026 earnings at $2.47 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. The company had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. Corcept Therapeutics’s revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.28 earnings per share.

Several other equities analysts have also commented on CORT. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Truist Financial upped their price objective on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a report on Monday, September 30th. Finally, StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $65.25.

Corcept Therapeutics Stock Down 3.7 %

Shares of NASDAQ:CORT opened at $59.99 on Thursday. The firm has a market capitalization of $6.29 billion, a P/E ratio of 47.61 and a beta of 0.56. The stock has a 50 day moving average price of $55.16 and a 200-day moving average price of $45.77. Corcept Therapeutics has a 52-week low of $20.84 and a 52-week high of $62.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Insiders Place Their Bets

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.88, for a total value of $131,736.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Guyer sold 6,606 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $48.97, for a total transaction of $323,495.82. Following the sale, the insider now directly owns 5,796 shares in the company, valued at approximately $283,830.12. The trade was a 53.27 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,011 shares of company stock valued at $1,951,268. Insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CORT. Synergy Asset Management LLC grew its position in Corcept Therapeutics by 131.3% in the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock worth $22,369,000 after purchasing an additional 262,503 shares during the period. Pacer Advisors Inc. grew its holdings in shares of Corcept Therapeutics by 18.3% in the fourth quarter. Pacer Advisors Inc. now owns 10,896 shares of the biotechnology company’s stock worth $549,000 after acquiring an additional 1,689 shares during the period. KBC Group NV increased its position in Corcept Therapeutics by 45.9% during the fourth quarter. KBC Group NV now owns 4,118 shares of the biotechnology company’s stock valued at $208,000 after acquiring an additional 1,296 shares during the last quarter. Blue Trust Inc. lifted its holdings in Corcept Therapeutics by 47.8% in the fourth quarter. Blue Trust Inc. now owns 17,225 shares of the biotechnology company’s stock valued at $797,000 after acquiring an additional 5,567 shares during the period. Finally, Linden Thomas Advisory Services LLC boosted its position in Corcept Therapeutics by 2.1% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 63,224 shares of the biotechnology company’s stock worth $3,186,000 after purchasing an additional 1,300 shares during the last quarter. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.